活血化瘀开窍法对大鼠缺血再灌注脑组织NOS及自由基的影响

目的：研究活血化瘀开窍法对脑缺血再灌注模型大鼠脑组织一氧化氮合成酶（NOS）及自由基的影响。方法：48组大鼠随机分为6组,脑醒冲剂高,中,低剂量组,尼莫通组,模型组,假手术组,分别测定NOS,LPO,SOD,GSH－Px,并作统计学处理。结果：活血化瘀开窍中药能适度提升脑组织NOS浓度,并能提高SOD,GSH－Px的的活性,降低LPO水平（与模型组比较,P＜0．01或P＜0．05）。结论：活血化瘀方药对大鼠急性缺血再灌注脑损伤具有保护作用。     

老年糖尿病肾病中药治疗前后血脂、过氧化物歧化酶的变化

目的研究益肾活血中药对老年临床糖尿病肾病（ＤＮ）的疗效和机制。方法６８例老年临床糖尿病肾病患者随 机分为治疗组（３４例,服降糖药加益肾活血中药）与对照组（３４例,仅服降糖药）。测定治疗前后患者血脂、过氧化物 歧化酶（ＳＯＤ）及血清过氧化脂质（ＬＰＯ）含量及 ２４ ｈ尿蛋白定量的变化,并分别与 ３０名健康人组作比较。结果老 年临床糖尿病患者 ＳＯＤ明显低于健康人组（Ｐ＜０．０５）,而血脂、ＬＰＯ及 ２４ ｈ尿蛋白定量均明显高于健康人组（Ｐ＜０．０１）。 治疗 ４周后治疗组 ＳＯＤ水平明显升高（Ｐ＜０．０５）,血脂、ＬＰＯ及 ２４ ｈ尿蛋白定量明显下降,与对照组相比有显著性差 异（Ｐ＜０．０５）。结论益肾活血中药对抗过氧化损伤、防治老年ＤＮ有临床意义。     

左右侧星状神经节阻滞对冠脉循环影响的实验研究

目的探讨左右侧星状神经节阻滞(SGB)对左冠状动脉急性闭塞区域的心肌组织血流及心肌血氧供需关系的影响.方法取犬24只,急性闭塞左冠状动脉前降支后,随机分为三组.对照组不进行SGB(6只);右侧SGB组(9只);左侧SGB组(9只),观察血液流变学有关指标变化.结果①左冠状动脉前降支闭塞后,心率(HR)、左冠状动脉回旋支血流量(CoBF)、左心室舒张期终末压(EDP)、心肌氧摄取率(MOER)显著增加(P＜0.05);闭塞区域心肌组织血流量(CBF)、心率血压双乘积(RPP)显著减少(P＜0.05);但三组间差异无显著性.②左SGB后HR、舒张期动脉血压(dBP)、CoBF、CBF无显著变化;左颈动脉血流量(LCaBF)、EDP、MOER、RPP与阻滞前相比有意义增加(P＜0.05).③右SGB后,EDP阻滞前后相比有意义增加(P＜0.05);HR、CoBF、RPP显著减少(P＜0.05).④HR、LCaBF、RPP、CoBF左右不同侧变化差异有显著性(P＜0.05).对照组左冠状动脉前下支闭塞后15min和30min各项测定指标没有显著性变化.结论急性左冠状动脉前降支闭塞导致的MOER、RPP的增加,左SGB无改善作用,并使其进一步增加;而右侧SGB后引起HR、CoBF、RPP显著减少.提示急性心肌梗塞时,左SGB有可能使心肌缺血、缺氧恶化,而右侧SGB在解除心脏疼痛的同时可减少心肌的耗氧量,因而有治疗作用.     

Is anticoagulation with bivalirudin comparable to heparin for pediatric extracorporeal life support? Results from a high‐volume center

There is a paucity of data regarding the use of direct thrombin inhibitors such as bivalirudin for children on extracorporeal life support (ECLS). We sought to compare the outcomes of children on ECLS anticoagulated with bivalirudin versus heparin. Patients transitioned from heparin to bivalirudin were treated as a separate group. A single‐institution, retrospective review of all consecutive children (neonate to 18 years) placed on ECLS in the cardiac or pediatric intensive care units was performed (June 2018‐December 2019). Data collected included demographics, anticoagulation strategy, number of circuit interventions, blood product use on ECLS, survival to decannulation, and survival to discharge. Fifty‐four children were placed on ECLS for a total of 56 runs. Demographics and venovenous versus venoarterial ECLS were similar. The bivalirudin group had longer median duration of support compared to the heparin group––11.0 days [IQR 6.2, 23.1] versus 3.3 days [2.1, 6.2], P < .001. Patients switched from heparin to bivalirudin had a similar duration of support (10.3 days [8.3, 18.3]) as those on bilvalirudin alone. However, there was no difference in red blood cell, fresh frozen plasma, or platelet transfusions. There was no difference in the number of circuit interventions, survival to decannulation or discharge. The freedom to first circuit intervention was longer with bivalirudin compared to heparin. Our data suggest that even with longer pediatric ECLS runs on bivalirudin, there were no differences in the outcomes between the heparin and bivalirudin groups, with longer freedom from first circuit intervention with bivalirudin. While this is the largest reported series comparing children on ECLS anticoagulated with heparin versus bivalirudin, larger studies are needed to determine the optimal anticoagulation strategy for this diverse and complicated group of children.     

Outcomes and factors associated with early mortality in pediatric postcardiotomy veno‐arterial extracorporeal membrane oxygenation

Mortality and morbidity of children received veno‐arterial extracorporeal membrane oxygenation (VA‐ECMO) support after cardiac surgery remain high despite remarkable advances in medical management and devices. The purpose of this study was to describe outcomes and risk factors of applying VA‐ECMO in the surgical pediatric population. We retrospectively analyzed 85 consecutive pediatric patients (aged <18 years) who received postcardiotomy VA‐ECMO from January 2010 to December 2018. Median (IQR) age at ECMO implantation in this cohort was 12.7 (6.4, 43.2) months, median weight was 8.5 (6.0, 12.8) kg, mean ECMO duration was 143.2 ± 81.6 hours and mean hospital length of stay was 48.4 ± 32.4 days. Seventy‐five patients (88.2%) were indicated for postcardiotomy cardiogenic shock. The successful ECMO weaning rate was 70.6% and in‐hospital mortality was 52.9%. The most common diagnosis was transposition of great arteries (n = 18, 21.2%), while acute kidney injury occurred most often (n = 64, 75.3%). Multivariate logistic regression analysis showed that thrombocytopenia, hemolysis, and nosocomial infection were positively correlated with in‐hospital mortality. Multivariate Cox proportional hazard regression analysis presented that thrombocytopenia significantly increased the 180‐day mortality in patients with successful weaning. Therefore, multiple factors had adverse effects on prognosis. Patient selection and procedures from ECMO implantation to weaning need to be closely monitored and performed in a timely manner to improve outcome.     

A novel approach to delivery of extracorporeal support using a modified continuous flow ventricular assist device in a mid‐volume congenital heart program

Extracorporeal life support (ECLS) is an essential component of a modern congenital cardiac surgery program. The circuit components and bedside management team may, however, vary among institutions. Here, we evaluate our initial experience with a modified ventricular assist device—based ECLS circuit primarily managed by the bedside nurse. We hypothesize that our outcomes are comparable to Extracorporeal Life Support Organization (ELSO) registry data. All patients who received ECLS from January 1, 2016 to December 31, 2019 at a single institution were included. Primary outcomes were survival to ECLS decannulation and discharge or transfer. Secondary outcomes included complications from ECLS. Data were compared to available ELSO registry data. Thirty‐seven patients underwent 44 ECLS runs during the study period. Forty percent of patients had single ventricle physiology. Nearly 46% of patients received ECLS as part of extracorporeal cardiopulmonary resuscitation (eCPR). Survival to ECLS decannulation (68.2%) and survival to discharge or transfer (61.4%) did not differ from overall ELSO outcomes (69.7%, P = .870 and 50.7%, P = .136), as well as survival to discharge or transfer in a comparable cohort of ELSO centers (53.1%, P = .081). Patients with complications had a lower rate of survival to discharge or transfer but this did not reach statistical significance (47.7% vs. 75.0%, P = .455). Neurologic (50.0%), hemorrhagic (45.5%), and renal complications (31.8%) were most common in this cohort. A modified ventricular assist device‐based ECLS circuit with primary management by the bedside nurse can provide comparable support in a neonatal and pediatric cardiac surgery population. Cost analyses and further delineation of the complication profile are necessary for a complete characterization of this system.     

Relationship between Pathological Characteristics and Radiological Findings on Perfusion MR Imaging of Meningioma

Few studies have reviewed the roles of perfusion magnetic resonance (MR) imaging in the histopathological examination of meningiomas. We analyzed the relationships between radiological findings on perfusion MR imaging and pathological characteristics such as origin of the tumor, mitotic activity, pathological subtype, and perifocal edema formation. The subjects were 21 surgical cases of meningioma preoperatively evaluated by perfusion MR imaging. A region of interest (ROI) was set inside of the tumor, and perifocal edema of the same size, cerebral blood volume (CBV), and cerebral blood flow (CBF) on perfusion MR and diffusion-weighted (DW) imaging were analyzed. These radiological data were evaluated in comparison with histopathological characteristics. On perfusion MR imaging, the average ratio of CBV against the contralateral side was 6.43 (1.13–20.0) and that of CBF was 7.73 (1.34–11.3). There was no significant relationship with perfusion MR imaging data, tumor volume, or perifocal edema volume. However, the large peritumoral edema group often had a higher CBV and CBF than the non-large peritumoral edema group. The skull base group had a significantly higher CBV and lower signal intensity on DW images than the non-skull base group. Signal intensity on DW images was higher in grade II or III than in grade I. Perfusion MR imaging data revealed that the higher ratio of peritumoral edema against tumor size was associated with higher blood flow and blood volume under intratumoral circulatory conditions, and that skull base meningioma had a higher blood volume than non-skull base meningioma.     

Urgent desensitization in patients bridged to heart transplantation under extracorporeal membrane oxygenation support: A preliminary experience

Antihuman leukocyte antigen (HLA) antibodies restrict the access to cardiac allografts. Desensitization therapy is a major challenge in patients with cardiogenic shock waiting for urgent heart transplantation (HT). We retrospectively reviewed six patients (mean age of 37.5 years [16–70]) who underwent plasmapheresis (PP) under extracorporeal membrane oxygenation (ECMO) before transplant between January 2017 and September 2018. The average duration of follow‐up was 25 months [20–32]. Mean fluorescence intensity (MFI) of HLA‐specific antibodies was reported as follows: score 4 for MFI < 1000, score 6 for 1000 < MFI < 3000 and score 8 for MFI > 3000. The mean duration of ECMO support was 29 days [1–74] and 6.8 [1–29] PP sessions were performed per patient before transplant. The mean number of HLA‐specific antibodies before HT was 9.6 for score 6 [4–13] and 5.8 for score 8 [1–12]. Four patients had major complications after transplantation (2 hemorrhagic shocks, 5 infectious events). Mean MFI reduction rate was 94% [79–100] for Class I and 44.2% for Class II [0–83]. Hospital survival was 100%, and early antibody‐mediated rejection was diagnosed in one patient at 7 days after HT. Plasmapheresis under ECMO support was associated with favorable early outcomes in highly sensitized candidates for urgent heart transplantation.     

Extra-cardiac collateral to an anomalous origin right coronary artery in a post-PTCA,post-CABG patient

In the context of collateral circulation of the heart, the role of extra-cardiac collateral arteries has been thought to be negligible. We present a case in which such collateral vessel acted as a rescue, subsequent to a failed revascularisation attempt. With surgeons nowadays considering ‘less is more’ in terms of grafting in coronary artery bypass grafting (CABG), and more evidence arising in favour of medical therapy, we need to re-assess the role of these collateral vessels in the coronary circulation.     

基于数据挖掘的益气活血类方防治脑缺血再灌注损伤用药规律及其作用机制研究

目的 探讨急性缺血性卒中溶栓治疗后使用益气活血类方剂干预的用药规律,预测核心药物防治脑缺血再灌注损伤的潜在作用机制。方法 检索中国知网、万方、维普和PubMed数据库中急性缺血性卒中溶栓治疗后使用益气活血类方有效干预的文献,对方中使用的药物进行频数、聚类及关联分析,依据关联规则选取置信度和支持度最高的核心药物,构建核心药物-活性成分-交集靶点网络图,并进行基因本体（gene ontology,GO）功能富集和京都基因与基因组百科全书（Kyoto encyclopedia of genes and genomes,KEGG）通路富集分析。结果 共筛选纳入232篇文献,涉及中药处方177首,包含中药119味,累计使用频次1903,以黄芪为首的高频药物28味,所有药物按功效可分为16种,药味总频次191,归经总频次292。高频药物聚类分析得到5个聚类,关联规则分析得到20组支持度较高的中药组合,其中支持度与置信度最高的二联药物组合为“黄芪-川芎”,三联药物组合为“黄芪-川芎-地龙”。网络药理学分析收集黄芪、川芎、地龙的活性成分30个;筛选“黄芪-川芎”防治脑缺血再灌注损伤的靶点91个,“黄芪...